Bioscience gives back to industry partners working overtime
Bioscience workers putting in overtime + restaurants in need of business = Perfect chance to give back.
Bioscience workers putting in overtime + restaurants in need of business = Perfect chance to give back.
Sioux Falls-based SAB Biotherapeutics is joining with global biotherapeutics leader CSL Behring to rapidly develop SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation by early summer.
Sioux Falls-based SAB Biotherapeutics will receive up to $27 million from the U.S. Department of Defense to develop and test a rapid response antibody program .
SAB Biotherapeutics, a Sioux Falls immunotherapy company rapidly working to develop a therapeutic specific to COVID-19, announced it is delaying its planned development at the USD Discovery District for at least one year.
“It takes time, but we absolutely believe we are capable of producing a therapeutic response to this virus faster than anyone, and that’s what we are putting into place now.” As the world battles COVID-19, this Sioux Falls company is fighting back in a big way.
Sioux Falls-based SAB Biotherapeutics has entered into multiple collaboration and option agreements with Pennsylvania-based CSL Behring, a global biotherapeutics company that has more than 20,000 employees.
A biopharmaceutical industry veteran is piloting SAB Biotherapeutics’ immunotherapy products to market.
SAB Biotherapeutics has raised $22 million in its Series A-2 round, which closed Dec. 15.
South Dakota Equity Partners has its first investment: A homegrown biotech company with big promise.
“There has never been a platform, at least in my experience, that has been able to do so much so quickly.” The science being done at SAB Biotherapeutics could be huge, not just for South Dakota but for human disease. We got a rare look at where it all will start.